Welcome Guest
Sign In
Register
Products
Popular Categories
Antibody Search
ELISA Kit Search
Biomolecules
Flow Cytometers
Thermal Cyclers
Microscopes
Transfection Reagents
Featured Products
New Products
Applications
ELISA
Western Blot
3D Cell Culture
Spatial Biology
PCR
Quantitative PCR
Digital PCR
Cell and Gene Therapy
In Vivo Models
Resources
eBooks
Bench Tips
Tech Insights
Editorial Articles
News
Product Reviews
Future Lab
Application Notes
Infographics
Events
Promotions
Multimedia
Biocompare Webinars
Technologies Transforming Precision Medicine
Immunotherapy
Reproducibility
Transformative Technologies
Podcasts
Bench Tip Videos
All Videos and Webinars
Life Science Webinars
Write a Review
Antibodies
Kits/Reagents
Equipment
Services
Register
Sign In
Biocompare
Products
Antibodies
Antibodies
Durvalumab
Durvalumab from MedChemExpress
Be the first to write a review!
Citations:
(8)
Supplier Page
Supplier Page from
MedChemExpress for
Durvalumab
Bulk Request
Description
Durvalumab (MEDI 4736) is an human anti-
PD-L1
monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of
PD-L1
to both
PD-1
and
CD80
, with
IC
50
s of 0.1 and 0.04 nM, respectively
Product Specs
Company Info
Citations
Reviews
Product Specs
Item
Durvalumab
Company
MedChemExpress
Price
$280.00
Supplier Page
View Company Product Page
Catalog Number
HY-P9919
Applications
Bioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity
99.60%
Research Area
Cancer
Type
Chemical
Quantity
1 mg
Molecule Name
Durvalumab
Add to Compare List
MedChemExpress
1 Deer Park Drive, Suite F
MONMOUTH JUNCTION
,
NJ
08852
United States
Phone
: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910
Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com
Company Profile
Website:
medchemexpress.com
Citations (8)
(1)
SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies
iScience
August 21, 2026
Bell Xi Wu, Xiaozhuo Ran, Olivia Huang, Lifang Song, Vivek Philip, Adrian Sacher, Ming-Sound Tsao, Benjamin H. Lok
N/A Brefeldin A Solution (1000X),
eBioscience
,Cat#
00-4506-51
; RRID: N/A
Durvalumab
,
MedChemExpress
,Cat#
HY-P9919
; RRID: N/A ,,
Experimental models
: Cell lines,
Experimental models
: Cell lines,
Experimental models
:
(2)
USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion
J Immunother Cancer
June 8, 2026
Yananlan Chen, Xiao Xu, Shenye Shao, Jiawei Zhang, Ziyang Wang, Changan Chen, Wangjie Jiang, Jiang Chang, Ruixiang Chen, Tao Zhou,
et al.
S5. Chemicals CHX: HY-12320 (50 µg/mL,
MCE
); MG132:
HY-13259
(10 µmol/L for 6 hours, MCE); durvalumab:
HY-P9919
(5 mg/kg,
MCE
);
ML-323
:
HY-17543
(10 mg/kg,
MCE
);
T0070907
:
HY-13202
(10 µmol/L for 24 hours,
MCE
);
(3)
A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden
Cell Chemical Biology
January 16, 2025
Olivia N. Rebeck, Miranda J. Wallace, Jerome Prusa, Jie Ning, Esse M. Evbuomwan, Sunaina Rengarajan, LeMoyne Habimana-Griffin, Suryang Kwak, David Zahrah, Jason Tung,
et al.
AB_10949073) Anti-human PD-L1 (B7-H1),
BioXCell
,Cat#
BE0285
(RRID: AB_2687808)
Durvalumab
,
MedChemExpress
,Cat#
HY-P9919
Atezolizumab
,
MedChemExpress
,Cat#
HY-P9904
Anti-StrepII-tag,
Abcam
,Cat#
ab180957
FITC anti-mouse CD3ε
,
BioLegend
,Cat#
100306
(4)
Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters
Nature communications
June 6, 2023
Nishi W, Wakamatsu E, Machiyama H, Matsushima R, Saito K, Yoshida Y, Nishikawa T, Takehara T, Toyota H, Furuhata M,
et al
.
(
1:10,000
, Cappel,
55550
), pembrolizumab (
MCE
,
HY-P9902
), nivolumab (
MCE
,
HY-P9903
), durvalumab (
MCE
,
HY-P9919
), and atezolizumab (
MCE
,
HY-P9904
), APC-anti-human IgG (H + L) (2.5 μg/ml,
Jackson Immuno
Research,
(5)
Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors
Biomedicines
July 26, 2022
Yohan Walter, Anne Hubbard, Allie Benoit, Erika Jank, Olivia Salas, Destiny Jordan, Andrew Ekpenyong
margins. Effective, clinically relevant
in vitro
concentrations of durvalumab (Fisher
MedChemExpress
HY-P9919
) are generally not as well standardized as those for temozolomide, as some clinical trials are still
(6)
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II
Cell reports
February 8, 2022
Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K,
et al
.
Dong’s lab,"(Liu et al., 2016)"
Atezolizumab
,
MedChemExpress
,Cat#
HY-P9904
Durvalumab
,
MedChemExpress
,Cat#
HY-P9919
Control human IgG,Thermo Fisher Scientific,Cat#02-7102;RRID:AB_2532958 Bacterial and
virus
strains
,Bacterial
(7)
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
Drug design, development and therapy
January 1, 2018
Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.
(8)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Cancer immunology research
September 1, 2015
Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J,
et al
.
<<
<
>
>>
Reviews
Be the First to Write a Review!
Durvalumab from MedChemExpress
Supplier Page
View Company Product Page
$280.00
Product Specs
Company Info
Citations
Reviews
Back To Top